The principal efficacy endpoint may be the summed pain intensity difference over 1-hour.

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute agony AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the advancement and commercialization of innovative therapies for the treatment of moderate-to-severe severe and breakthrough pain, today announced the initiation of an open-label Stage 3 study of ARX-04 for the treatment of adult patients who within the er with moderate-to-severe acute agony connected with trauma or damage reviews . The principal efficacy endpoint may be the summed pain intensity difference over 1-hour . Security endpoints, such as for example adverse events and essential signs may also be assessed, as will the sufferers' and healthcare providers' satisfaction with the technique of pain control.

AcelRx completes private placement of common stock AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical organization focused on the advancement and commercialization of innovative treatments for the treating acute and breakthrough pain, announced today that it finished its previously announced personal placement of common stock and warrants to get common share on June 1, 2012.0 million. Related StoriesCombatting viral and bacterial lung attacks with volatile anesthetics: an interview with Dr ChakravarthyBRCA gene mutations and ovarian malignancy: an interview with Dr Matulonis, Harvard Medical SchoolScripps Florida researchers win $2.4 million to expand development of new suffering therapiesAcelRx issued an aggregate of 2,922,337 newly-issued shares of common stock and warrants to purchase up to 2,630,103 extra shares of common stock..